Navigation Links
Xmark Requests That Icagen Oust Its CEO and Pursue Strategic Alternatives, and Calls on Board Members to Resign
Date:4/1/2009

RIDGEFIELD, Conn., April 1 /PRNewswire/ -- On April 1, 2009, Xmark Opportunity Partners, LLC, the sole member of the investment manager of Xmark Opportunity Fund, L.P. and Xmark Opportunity Fund, Ltd., sent the following letter to the Board of Directors of Icagen, Inc. (Nasdaq: ICGN).

                            XMARK OPPORTUNITY PARTNERS, LLC
                                    90 Grove Street
                                       Suite 201
                             Ridgefield, Connecticut 06877

                                                               April 1, 2009
    VIA E-MAIL
    Board of Directors
    Icagen, Inc.
    4222 Emperor Boulevard
    Suite 350
    Durham, NC  27703

Lady and Gentlemen:

There are four words that no one ever wants to say: I told you so. For almost a year, we have been telling you to pursue strategic alternatives; we told you so when Icagen had a higher stock price, more cash and a cleaner profile for its compounds. We have been telling you so as the markets have fallen further and further, and as the company's cash on hand has fallen concomitantly.

We believe that the management team and the Board of Directors have failed miserably and repeatedly. In an era where stalwart companies such as General Motors, Citigroup and Lehman Brothers have had high-level management turnover due to the failure of their respective management teams, in our opinion, there is absolutely no reason why Icagen should not follow suit.

Accordingly, we call on the Board to immediately (a) initiate a public search for a replacement Chief Executive Officer, (b) hire an investment banker to evaluate and pursue strategic alternatives so that the company's shareholders are not left holding a "zero" in the near to mid-term, and (c) remove the recently-adopted poison pill.

Once both a new chief executive and a process are in place, Board members Dr. Charles A. Sanders, Lead Director of Genentech, Inc., and Anthony B. Evnin, Managing General Partner of Venrock Associates, should resign, as they have been front and center in our dialogue with the company, and have ignored our sound advice.

Respectfully submitted,

XMARK OPPORTUNITY PARTNERS, LLC

About the Xmark Funds

The Xmark Funds are dedicated to making investments in publicly-traded, small-cap life sciences companies and seek to achieve substantial capital appreciation by investing directly in public life sciences companies trading at venture-level valuations. The Xmark Funds conduct extensive fundamental due diligence and tailor their investments to the risk/reward profile of each target.

The team's investment professionals have worked together since founding the investment manager in 2001. The investment team includes life sciences professionals with extensive experience and expertise in clinical research, business development, medical practice, hospital and physician practice management, asset management and law.


'/>"/>
SOURCE Xmark Opportunity Partners, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Biotechnology Value Fund, L.P. Requests Avigen Board to Provide Critical Information to Stockholders
2. deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter
3. CryoCor Requests International Trade Commission Investigation Into CryoCath for Patent Infringement
4. Sinovac Requests Extension for Annual Shareholders Meeting
5. Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education
6. XTENT to Retain Investment Bank to Pursue Strategic Alternatives
7. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
8. Covance Decides to Pursue Its Original Preclinical Strategy in China
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
11. AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells ... of an Asia-Pacific Symposium as other research and development initiatives for potential stem cell ... and top Global Stem Cells Group executives began meeting to establish a working agenda ...
(Date:4/27/2016)... 2016 ReportsnReports.com adds 2016 ... focus on US, EU, China ... the healthcare business intelligence collection of its growing ... report on the Flow Cytometry market spread across ... 282 tables and figures is now available at ...
(Date:4/26/2016)... ... 26, 2016 , ... BaseHealth , the comprehensive predictive ... as Chief Business Officer. Arianpour, a genomics pioneer and visionary commercial leader with ... recently Chief Commercial Officer of Pathway Genomics. He has held senior executive roles ...
(Date:4/26/2016)... ... 2016 , ... Heidelberg Instruments, a leader in design, development ... Volume Pattern Generator (VPG) line of lithography systems. The breakthrough VPG+ system is ... a solution for mid volume direct write lithography applications. It utilizes the ...
Breaking Biology Technology:
(Date:3/21/2016)... Unique technology combines v ... security   Xura, Inc. ... digital communications services, today announced it is working alongside ... customers, particularly those in the Financial Services Sector, the ... within a mobile app, alongside, and in combination with, ...
(Date:3/15/2016)... March 15, 2016 --> ... by Transparency Market Research "Digital Door Lock Systems Market - ... - 2023," the global digital door lock systems market in ... 2014 and is forecast to grow at a CAGR of ... small and medium enterprises (MSMEs) across the world and high ...
(Date:3/14/2016)... 2016 http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ... --> DERMALOG, le leader de ... lecteurs d,empreintes digitales pour l,enregistrement des réfugiés en ... pour produire des cartes d,identité aux réfugiés. DERMALOG ...
Breaking Biology News(10 mins):